CA2384192C - Composition pharmaceutique renfermant de l'huile d'eucalyptus et de l'huile d'orange - Google Patents

Composition pharmaceutique renfermant de l'huile d'eucalyptus et de l'huile d'orange Download PDF

Info

Publication number: CA2384192C
Authority: CA; Canada
Prior art keywords: oil; eucalyptus oil; orange oil; percent; pharmaceutical composition
Prior art date: 1999-09-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2384192A

Other languages

English (en)

Other versions

CA2384192A1 (fr

Inventor

Henning Ueck

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

G Pohl Boskamp GmbH and Co KG

Original Assignee

G Pohl Boskamp GmbH and Co KG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-16

Filing date

2000-09-12

Publication date

2018-10-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8078793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2384192(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-09-12 Application filed by G Pohl Boskamp GmbH and Co KG filed Critical G Pohl Boskamp GmbH and Co KG

2001-03-22 Publication of CA2384192A1 publication Critical patent/CA2384192A1/fr

2018-10-02 Application granted granted Critical

2018-10-02 Publication of CA2384192C publication Critical patent/CA2384192C/fr

2020-09-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000010642 eucalyptus oil Substances 0.000 title claims abstract description 58
229940044949 eucalyptus oil Drugs 0.000 title claims abstract description 58
235000019502 Orange oil Nutrition 0.000 title claims abstract description 52
239000010502 orange oil Substances 0.000 title claims abstract description 52
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
201000010099 disease Diseases 0.000 claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
210000002345 respiratory system Anatomy 0.000 claims abstract description 6
239000000203 mixture Substances 0.000 claims description 8
239000007903 gelatin capsule Substances 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
239000006188 syrup Substances 0.000 claims description 3
235000020357 syrup Nutrition 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims 2
239000004615 ingredient Substances 0.000 claims 2
244000005700 microbiome Species 0.000 abstract description 2
239000000902 placebo Substances 0.000 description 16
229940068196 placebo Drugs 0.000 description 16
239000003242 anti bacterial agent Substances 0.000 description 14
229940088710 antibiotic agent Drugs 0.000 description 12
206010006451 bronchitis Diseases 0.000 description 12
210000004027 cell Anatomy 0.000 description 9
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 8
239000003921 oil Substances 0.000 description 8
235000019198 oils Nutrition 0.000 description 8
206010011224 Cough Diseases 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
229960001668 cefuroxime Drugs 0.000 description 5
206010042566 Superinfection Diseases 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
239000005414 inactive ingredient Substances 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
FUWVMBCPMRAWPG-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-hydroxyoctadecanoate Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)OCC(O)CO FUWVMBCPMRAWPG-UHFFFAOYSA-N 0.000 description 2
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010036790 Productive cough Diseases 0.000 description 2
241000295644 Staphylococcaceae Species 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
229960003511 macrogol Drugs 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000004302 potassium sorbate Substances 0.000 description 2
229940069338 potassium sorbate Drugs 0.000 description 2
235000010241 potassium sorbate Nutrition 0.000 description 2
239000008213 purified water Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
208000024794 sputum Diseases 0.000 description 2
210000003802 sputum Anatomy 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229940099369 (+)- limonene Drugs 0.000 description 1
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
GRWFGVWFFZKLTI-RKDXNWHRSA-N (+)-α-pinene Chemical compound CC1=CC[C@H]2C(C)(C)[C@@H]1C2 GRWFGVWFFZKLTI-RKDXNWHRSA-N 0.000 description 1
GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000702244 Orthoreovirus Species 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
235000019484 Rapeseed oil Nutrition 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000017574 dry cough Diseases 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229940087305 limonene Drugs 0.000 description 1
235000001510 limonene Nutrition 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000001562 sternum Anatomy 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
231100000186 toxicological potential Toxicity 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Botany (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA2384192A 1999-09-16 2000-09-12 Composition pharmaceutique renfermant de l'huile d'eucalyptus et de l'huile d'orange Expired - Lifetime CA2384192C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE29916014.9		1999-09-16
DE29916014U DE29916014U1 (de)	1999-09-16	1999-09-16	Pharmazeutische Zusammensetzung, umfassend Eukalyptus- und Orangenöl
PCT/EP2000/008903 WO2001019382A1 (fr)	1999-09-16	2000-09-12	Composition pharmaceutique comprenant de l'huile d'eucalyptus et d'orange

Publications (2)

Publication Number	Publication Date
CA2384192A1 CA2384192A1 (fr)	2001-03-22
CA2384192C true CA2384192C (fr)	2018-10-02

Family

ID=8078793

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2384192A Expired - Lifetime CA2384192C (fr)	1999-09-16	2000-09-12	Composition pharmaceutique renfermant de l'huile d'eucalyptus et de l'huile d'orange

Country Status (12)

Country	Link
US (2)	US6800305B1 (fr)
EP (1)	EP1212072B1 (fr)
CN (2)	CN101601764B (fr)
AT (1)	ATE261732T1 (fr)
AU (1)	AU781039B2 (fr)
CA (1)	CA2384192C (fr)
DE (2)	DE29916014U1 (fr)
DK (1)	DK1212072T3 (fr)
ES (1)	ES2220546T3 (fr)
MX (1)	MXPA02002791A (fr)
NZ (1)	NZ517976A (fr)
WO (1)	WO2001019382A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE29916014U1 (de) *	1999-09-16	2001-02-08	Akh Arzneimittelkontor Hamburg	Pharmazeutische Zusammensetzung, umfassend Eukalyptus- und Orangenöl
ES2173816B1 (es) *	2001-04-11	2004-01-01	Merino Antonio Monino	Composicion de un producto para la eliminacion de toda clase de virus y bacterias.
RU2207143C1 (ru) *	2002-06-27	2003-06-27	Общество с ограниченной ответственностью Фирма "ЭЙКОСЪ"	Биологически активная добавка "бронхоастмин" для профилактики и поддерживающей терапии бронхиальной астмы и воспалительных заболеваний органов дыхания
US7220436B2 (en) *	2004-05-07	2007-05-22	Phyzz, Inc.	Composition for inhalation therapy and methods for use
RU2270688C1 (ru) *	2005-01-11	2006-02-27	Николай Владимирович Губарев	Способ изгнания гельминтов из организма человека
EP3964221A1 (fr) *	2020-09-07	2022-03-09	G. Pohl-Boskamp GmbH & Co. KG	Agents antiviraux
CN116265023B (zh) *	2021-12-16	2024-10-18	北京远大九和药业有限公司	一种预防和/或治疗耳部感染的药物组合物及其制备方法和用途
CN118662560A (zh) *	2024-06-28	2024-09-20	仙乐健康科技(安徽)有限公司	一种可缓解上呼吸道感染的柑橘提取物和桉叶油组合物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2444024A1 (de)	1974-09-14	1976-04-01	Wilhelm R Fleher	Mittel zur beseitigung von geruechen und abtoetung von bakterien
FR2504551A1 (fr) *	1981-04-24	1982-10-29	Dehais Claude	Compositions aromatiques possedant des proprietes biologiques et medicaments les renfermant
KR920005729B1 (ko) *	1984-09-06	1992-07-16	미쓰비시 레이온 캄파니 리미티드	방향성 섬유
DE4201179A1 (de)	1992-01-17	1993-07-22	Alfatec Pharma Gmbh	Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
DE69324523T2 (de)	1992-06-12	1999-09-09	Kao Corp.	Badezusatzzusammensetzung enthaltend oberflächenaktive Mittel enthaltende nahtlose Kapsel und Verfahren zur Herrstellung der Kapsel
DE4226174A1 (de) *	1992-08-07	1994-02-10	Solvay Fluor & Derivate	Polyglycerinfettsäureestergemisch
RU2038092C1 (ru) *	1992-10-16	1995-06-27	Роман Абрамович Дубинский	Способ повышения адаптационного уровня организма ребенка
WO1995013794A1 (fr)	1993-11-18	1995-05-26	Nippon Shinyaku Co., Ltd.	Procede pour produire une composition de medicament stable, et preparation pharmaceutique
US5888984A (en) *	1994-05-12	1999-03-30	Dermal Research Laboratories, Inc.	Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
TW412425B (en)	1994-10-18	2000-11-21	Kao Corp	Dentifrice composition having capsule particles
JPH08310931A (ja) *	1995-05-19	1996-11-26	Maruzen Pharmaceut Co Ltd	グルコシルトランスフェラーゼ阻害剤および口腔清浄化剤
US5716928A (en) *	1995-06-07	1998-02-10	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CH688787A5 (de) *	1995-09-05	1998-03-31	Dieter Linsig	Etherische Oele enthaltende Zusammensetzungen.
US5686074A (en) *	1996-08-07	1997-11-11	Stewart; Ulvert H.	Poison ivy treatment composition and method of use
GB9725291D0 (en) *	1997-11-28	1998-01-28	Barrier Hygiene Ltd	A disinfectant
US6444238B1 (en) *	2000-03-10	2002-09-03	General Cosmetics Corporation	Pain relief composition and method of relieving pain
US6495177B1 (en) *	1999-08-13	2002-12-17	Warner Chilcott Laboratories Ireland Limited	Orally dissolvable nutritional supplement
DE29916014U1 (de) *	1999-09-16	2001-02-08	Akh Arzneimittelkontor Hamburg	Pharmazeutische Zusammensetzung, umfassend Eukalyptus- und Orangenöl
US6342204B1 (en) *	1999-10-27	2002-01-29	Dakota Dental Development, Inc	Flavored tooth conditioning compositions and methods for using the compositions to condition a tooth surface
GB0022337D0 (en) *	2000-09-12	2000-10-25	Barrier Biotech Ltd	An antimicrobial composition

1999
- 1999-09-16 DE DE29916014U patent/DE29916014U1/de not_active Expired - Lifetime
2000
- 2000-09-12 DK DK00967663T patent/DK1212072T3/da active
- 2000-09-12 CN CN200910147510.0A patent/CN101601764B/zh not_active Expired - Lifetime
- 2000-09-12 CN CNB008129576A patent/CN100500175C/zh not_active Expired - Lifetime
- 2000-09-12 US US10/088,469 patent/US6800305B1/en not_active Expired - Lifetime
- 2000-09-12 ES ES00967663T patent/ES2220546T3/es not_active Expired - Lifetime
- 2000-09-12 EP EP00967663A patent/EP1212072B1/fr not_active Expired - Lifetime
- 2000-09-12 WO PCT/EP2000/008903 patent/WO2001019382A1/fr not_active Ceased
- 2000-09-12 DE DE50005714T patent/DE50005714D1/de not_active Expired - Lifetime
- 2000-09-12 AT AT00967663T patent/ATE261732T1/de active
- 2000-09-12 NZ NZ517976A patent/NZ517976A/en not_active IP Right Cessation
- 2000-09-12 MX MXPA02002791A patent/MXPA02002791A/es active IP Right Grant
- 2000-09-12 CA CA2384192A patent/CA2384192C/fr not_active Expired - Lifetime
- 2000-09-12 AU AU77757/00A patent/AU781039B2/en not_active Ceased
2003
- 2003-10-22 US US10/646,498 patent/US7087253B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1212072A1 (fr)	2002-06-12
WO2001019382A1 (fr)	2001-03-22
DE29916014U1 (de)	2001-02-08
US6800305B1 (en)	2004-10-05
NZ517976A (en)	2004-04-30
US20040076693A1 (en)	2004-04-22
ES2220546T3 (es)	2004-12-16
US7087253B2 (en)	2006-08-08
CN100500175C (zh)	2009-06-17
ATE261732T1 (de)	2004-04-15
MXPA02002791A (es)	2005-07-01
CN101601764A (zh)	2009-12-16
DK1212072T3 (da)	2004-06-21
DE50005714D1 (de)	2004-04-22
AU7775700A (en)	2001-04-17
CA2384192A1 (fr)	2001-03-22
AU781039B2 (en)	2005-05-05
EP1212072B1 (fr)	2004-03-17
CN1374868A (zh)	2002-10-16
CN101601764B (zh)	2014-05-21

Legal Events

Date	Code	Title	Description
2005-09-12	EEER	Examination request
2020-11-16	MKEX	Expiry	Effective date: 20200914

Publication	Publication Date	Title
JP2703594B2 (ja)	1998-01-26	リポソーム含有ニスタチン
US4496548A (en)	1985-01-29	Composition and method for reducing hangover
Hennequin et al.	1996	Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature
JPH09501702A (ja)	1997-02-18	増強された抗生物質組成物
KR20150008086A (ko)	2015-01-21	미생물 감염증의 국소 치료용 조성물
CA2384192C (fr)	2018-10-02	Composition pharmaceutique renfermant de l'huile d'eucalyptus et de l'huile d'orange
Murray et al.	1997	Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients
WO2020058836A1 (fr)	2020-03-26	Compositions pharmaceutiques et systèmes d'administration pour la prévention et le traitement de la candidose
CN1812802A (zh)	2006-08-02	用于治疗关节炎病症的制剂
Krüger et al.	1995	Experience with liposomal Amphotericin‐B in 60 patients undergoing high‐dose therapy and bone marrow or peripheral blood stem cell transplantation
WO1993011777A1 (fr)	1993-06-24	Composition d'amphotericine b a effet antifongique renforce
US5153221A (en)	1992-10-06	Method for the treatment of acquired immune deficiency syndrome
EP1317922B1 (fr)	2007-04-18	Preparation antipyretique renfermant du xylitol
DE1950403C3 (de)	1981-04-09	Pharmazeutische Zusammensetzung auf der Basis von Formaldehyd-Casein
CN118924715B (zh)	2025-03-21	布替萘芬在抗脓肿分枝杆菌感染中的应用
CN118924716B (zh)	2025-01-28	萘替芬在抗脓肿分枝杆菌感染中的应用
CN1943676A (zh)	2007-04-11	白英凝胶剂及其制备方法和应用
EP1902721A1 (fr)	2008-03-26	Compositions médicales et nutritionnelles à base de vaccinium macrocarpon
Cox	1973	Pharmacology of carbenicillin indanyl sodium in renal insufficiency
US3773959A (en)	1973-11-20	Fungicidal compositions comprising griseofulvin and thiabendazole and methods of utilizing same
CA2479381C (fr)	2011-11-01	Une utilisation du traitement des infections fongiques avec une formulation synergique d'agent antifongique, de menthol et d'acetate de menthyle
KR20050054712A (ko)	2005-06-10	파피리플라보놀 에이를 유효성분으로 하는 항균제 조성물
JPH1017484A (ja)	1998-01-20	真菌および白癬菌皮膚・粘膜感染症治療剤
Cartwright	1976	Oral Clotrimazole In The Treatment Of Füngal Infection
Gagana	2018	“Efficacy of Punica Granatum (Pomegranate) in the Management of Oral Candidiasis”–A Randomized Control Study